Bright Minds Biosciences Inc (DRUG) ニュース

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

-  Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data  ...

Form D - Notice of Exempt Offering of Securities

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG...

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

BMB-201 demonstrated dose-dependent efficacy in pain modelsBMB-201 demonstrated similar efficacy to morphine in...